Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<
The UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis drugs after NICE said “no” to regular NHS funding for its Epidyolex for rare forms of ch
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
